Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome

Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump... ORIGINAL CONTRIBUTION Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome P. Michael Ho, MD, PhD Context Prior mechanistic studies reported that omeprazole decreases the platelet Thomas M. Maddox, MD, MSc inhibitory effects of clopidogrel, yet the clinical significance of these findings is not clear. Li Wang, MS Objective To assess outcomes of patients taking clopidogrel with or without a pro- Stephan D. Fihn, MD, MPH ton pump inhibitor (PPI) after hospitalization for acute coronary syndrome (ACS). Robert L. Jesse, MD, PhD Design, Setting, and Patients Retrospective cohort study of 8205 patients with Eric D. Peterson, MD, MPH ACS taking clopidogrel after discharge from 127 Veterans Affairs hospitals between October 1, 2003, and January 31, 2006. Vital status information was available for all John S. Rumsfeld, MD, PhD patients through September 30, 2006. REATMENT WITH CLOPIDOGREL Main Outcome Measures All-cause mortality or rehospitalization for ACS. in addition to aspirin reduces Results Of 8205 patients taking clopidogrel after discharge, 63.9% (n=5244) were recurrent cardiovascular events prescribed PPI at discharge, during follow-up, or both and 36.1% (n=2961) were not Tfollowing hospitalization for prescribed PPI. Death or rehospitalization for ACS occurred in 20.8% http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome

Loading next page...
 
/lp/american-medical-association/risk-of-adverse-outcomes-associated-with-concomitant-use-of-t2N0tnJ0ZZ
Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2009.261
pmid
19258584
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome P. Michael Ho, MD, PhD Context Prior mechanistic studies reported that omeprazole decreases the platelet Thomas M. Maddox, MD, MSc inhibitory effects of clopidogrel, yet the clinical significance of these findings is not clear. Li Wang, MS Objective To assess outcomes of patients taking clopidogrel with or without a pro- Stephan D. Fihn, MD, MPH ton pump inhibitor (PPI) after hospitalization for acute coronary syndrome (ACS). Robert L. Jesse, MD, PhD Design, Setting, and Patients Retrospective cohort study of 8205 patients with Eric D. Peterson, MD, MPH ACS taking clopidogrel after discharge from 127 Veterans Affairs hospitals between October 1, 2003, and January 31, 2006. Vital status information was available for all John S. Rumsfeld, MD, PhD patients through September 30, 2006. REATMENT WITH CLOPIDOGREL Main Outcome Measures All-cause mortality or rehospitalization for ACS. in addition to aspirin reduces Results Of 8205 patients taking clopidogrel after discharge, 63.9% (n=5244) were recurrent cardiovascular events prescribed PPI at discharge, during follow-up, or both and 36.1% (n=2961) were not Tfollowing hospitalization for prescribed PPI. Death or rehospitalization for ACS occurred in 20.8%

Journal

JAMAAmerican Medical Association

Published: Mar 4, 2009

References